mBio
(Apr 2021)
Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features
Yannic C. Bartsch,
Carolin Loos,
Evan Rossignol,
Jesse M. Fajnzylber,
Dansu Yuan,
Anchalee Avihingsanon,
Sasiwimol Ubolyam,
Thidarat Jupimai,
Bernard Hirschel,
Jintanat Ananworanich,
Douglas A. Lauffenburger,
Jonathan Z. Li,
Galit Alter,
Boris Julg
Affiliations
Yannic C. Bartsch
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
Carolin Loos
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
Evan Rossignol
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
Jesse M. Fajnzylber
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Dansu Yuan
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
Anchalee Avihingsanon
HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Sasiwimol Ubolyam
HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Thidarat Jupimai
Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Bernard Hirschel
Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
Jintanat Ananworanich
Department of Global Health, University of Amsterdam, Amsterdam, The Netherlands
Douglas A. Lauffenburger
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
Jonathan Z. Li
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Galit Alter
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
Boris Julg
Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
DOI
https://doi.org/10.1128/mBio.00170-21
Journal volume & issue
Vol. 12,
no. 2
Abstract
Read online
Plasma viremia reoccurs in most HIV-infected individuals once antiretroviral therapy is interrupted, and interindividual differences in the kinetics of viral rebound have been associated with virological and immunological factors. Antibody features, including Fc functionality and Fc glycosylation, have been identified as sensitive surrogates for disease activity in multiple diseases.
WeChat QR code
Close
